Actual 10‐year survivors following resection of adrenocortical carcinoma

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with limited therapeutic options beyond surgical resection. The characteristics of actual long‐term survivors following surgical resection for ACC have not been previously reported.

[1]  S. Ferman,et al.  Recurrence and mortality prognostic factors in childhood adrenocortical tumors: Analysis from the Brazilian National Institute of Cancer experience , 2016, Pediatric hematology and oncology.

[2]  J. Sicklick,et al.  Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. , 2016, Journal of the American College of Surgeons.

[3]  K. Boudjema,et al.  An unusual case of adrenocortical carcinoma with liver metastasis that occurred at 23 years after surgery. , 2016, Hepatobiliary surgery and nutrition.

[4]  E. Kebebew,et al.  Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study , 2016, World Journal of Surgery.

[5]  G. Bednarek-Tupikowska,et al.  Current and emerging therapies for adrenocortical carcinoma--review. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[6]  W. Harmsen,et al.  Operative intervention for recurrent adrenocortical cancer. , 2013, Surgery.

[7]  V. Master,et al.  Association of tumor size with metastatic potential and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer Database. , 2013, The Canadian journal of urology.

[8]  E. Baudin,et al.  Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  M. Gonen,et al.  Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified? , 2012, Annals of Surgical Oncology.

[10]  P. Marotta,et al.  Hepatic Metastasis from Adrenocortical Carcinoma Fifteen Years after Primary Resection , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[11]  C. Nies,et al.  Impact of Lymphadenectomy on the Oncologic Outcome of Patients With Adrenocortical Carcinoma , 2012, Annals of surgery.

[12]  M. Makuuchi,et al.  The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience , 2009, Annals of surgery.

[13]  D. Bentrem,et al.  Adrenocortical carcinoma in the United States , 2008, Cancer.

[14]  J. Kievit,et al.  Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. , 2008, European journal of endocrinology.

[15]  M. Papotti,et al.  Adjuvant mitotane treatment for adrenocortical carcinoma. , 2007, The New England journal of medicine.

[16]  A. Meyer,et al.  32-year survival with metastatic adrenal cortical carcinoma--update of a case report. , 2007, Anticancer research.

[17]  J. Bertherat,et al.  Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  Electron Kebebew,et al.  Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress? , 2006, World Journal of Surgery.

[19]  S. Roman,et al.  Adrenocortical carcinoma , 2006, Current opinion in oncology.

[20]  S. Sidhu,et al.  Adrenocortical cancer: recent clinical and molecular advances , 2004, Current opinion in oncology.

[21]  M. Pelizzo,et al.  Adrenocortical carcinoma: a 15-year survival after complete resection and repeated resection. A retrospective study in a patient with an expected poor prognosis. , 2003, Anticancer research.

[22]  B. Lange,et al.  Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma. , 2002, The Journal of clinical endocrinology and metabolism.

[23]  P. Schultz,et al.  Adrenocortical carcinoma , 2001, Cancer.

[24]  I. Ilias,et al.  Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane , 2001, Journal of endocrinological investigation.

[25]  Y. Chapuis,et al.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group , 2001, World Journal of Surgery.

[26]  V. Budach,et al.  [Adrenal cortical carcinoma]. , 1999, Zhonghua wai ke za zhi [Chinese journal of surgery].

[27]  R. Bellantone,et al.  The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. , 1996, Surgery.

[28]  M. Okazaki,et al.  METASTATIC ADRENOCORTICAL CARCINOMA TREATED BY REPEATED RESECTION: A CASE REPORT OF LONG‐TERM SURVIVAL OVER 18 YEARS , 1995, International journal of urology : official journal of the Japanese Urological Association.

[29]  G. Fleuren,et al.  Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. , 1994, British Journal of Cancer.

[30]  M. Brennan,et al.  An eleven-year experience with adrenocortical carcinoma. , 1992, Surgery.

[31]  J. V. van Krieken,et al.  A case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications. , 1992, The Netherlands journal of medicine.

[32]  J. Norton,et al.  Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy. , 1991, Archives of surgery.

[33]  P Blondeau,et al.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.

[34]  L. Weiss.  Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors , 1984, The American journal of surgical pathology.

[35]  Yuhree Kim,et al.  Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes , 2015, Annals of Surgical Oncology.

[36]  F. Beuschlein,et al.  The role of surgery in the management of recurrent adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[37]  L. Chiche,et al.  Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. , 2006, Surgery.

[38]  K. Hess,et al.  Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer , 1993, Cancer.